Clinical Social Workers in Sparrows Point, MD Accepting Medicare
2 Clinical Social Workers found. Showing 1 - 2
 Mrs. Hazel J Hudson-parker, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4615 Sandwood Rd, Sparrows Point, MD 21219 Phone: 443-570-3537 |
Mrs. Abena Adoko Sando, MSW, LCSW-C Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 6302 N Point Rd, Unit C, Sparrows Point, MD 21219 Phone: 443-939-0513 |
News Archive
Survival of head and neck cancer patients is greatly affected by coexisting ailments
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.
AxoGen, LecTec sign merger agreement
LecTec Corporation announced today that on May 31, 2011 it entered into an Agreement and Plan of Merger ("Merger Agreement") with AxoGen Corporation, d/b/a AxoGen Inc., a privately held company focused on developing and commercializing medical products for the repair of peripheral nerve injuries.
Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.
Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
Accovion establishes two additional subsidiaries in the Czech Republic and in Russia
Accovion is a premier full service European CRO known for its expertise in managing and conducting international clinical trials. Accovion supports local and global projects of all types and phases for the pharmaceutical, biotechnology and medical device industries. Its services include study planning and management, clinical monitoring, pharmacovigilance including post-marketing safety, data management, biostatistics, statistical programming, medical writing and electronic publishing.
› Verified 6 days ago